BeyondSpring Reports 2025 Year-End Financial Results

Rhea-AI Summary

BeyondSpring (NASDAQ:BYSI) reported 2025 year-end results highlighting Phase 3 success for plinabulin in EGFR wild-type NSCLC and strategic progress at SEED Therapeutics.

Key facts: DUBLIN-3 showed OS HR 0.72 (p=0.0078) with median OS +2.5 months, grade 4 neutropenia reduced to 5%, DUBLIN-4 confirmatory trial planned (NCT07361484), SEED initiated Phase 1a for ST-01156, completed $30M Series A-3, and company cash was $12.6M as of Dec 31, 2025.

Positive

• OS hazard ratio 0.72 in DUBLIN-3 (p=0.0078)
• Median OS +2.5 months vs docetaxel in Phase 3 non-squamous NSCLC
• Grade 4 neutropenia reduced from >30% to 5% with plinabulin+docetaxel
• SEED first patient dosed in Phase 1a for ST-01156 after IND clearances
• $30 million Series A-3 financing completed for SEED

Negative

• Cash balance $12.6M as of Dec 31, 2025 (potential near-term funding pressure)
• R&D expenses +69% to $4.4M in 2025 vs $2.6M in 2024
• Net loss $8.7M from continuing operations; discontinued ops loss $5.5M

Key Figures

OS hazard ratio: HR 0.72 (p=0.0078) Median OS benefit: 2.5 months Neutropenia reduction: Grade 4: >30% to 5% (p<0.0001) +5 more

8 metrics

OS hazard ratio HR 0.72 (p=0.0078) DUBLIN‑3 non‑squamous NSCLC 24‑month analysis

Median OS benefit 2.5 months Plinabulin + docetaxel vs docetaxel in non‑squamous NSCLC

Neutropenia reduction Grade 4: >30% to 5% (p<0.0001) Safety profile in DUBLIN‑3

R&D expenses $4.4M Continuing operations, full‑year 2025 (vs. $2.6M in 2024)

G&A expenses $4.6M Continuing operations, full‑year 2025 (vs. $6.1M in 2024)

Net loss $8.7M Continuing operations, full‑year 2025 (vs. $8.9M in 2024)

Cash and equivalents $12.6M As of December 31, 2025

Discontinued ops net loss $5.5M SEED, full‑year 2025 (vs. $7.8M in 2024)

Market Reality Check

Price: $1.62 Vol: Pre‑announcement volume o...

low vol

$1.62 Last Close

Volume Pre‑announcement volume of 15,662 vs 20‑day average 26,979 suggests no elevated trading ahead of this release. low

Technical Shares at $1.62 were trading below the 200‑day MA of $1.88 before the results.

Peers on Argus

Among close biotech peers, moves were mixed: IMMX, OSTX, ALGS and IGMS were down...

2 Up

Among close biotech peers, moves were mixed: IMMX, OSTX, ALGS and IGMS were down while ACET was up; momentum scanners highlighted IMMX and CVM moving up, suggesting BYSI trading was not part of a broad, synchronized sector move.

Common Catalyst Same‑day peer news included OSTX receiving EMA ATMP designation, which is unrelated to BYSI’s earnings and clinical update.

Previous Earnings Reports

4 past events · Latest: Nov 12 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Nov 12	Q3 2025 earnings	Positive	-3.6%	Q3 2025 results with strong NSCLC data and SEED financing/IND milestones.
Aug 13	Q2 2025 earnings	Positive	-0.5%	Q2 2025 update featuring Plinabulin efficacy and SEED IND clearance.
May 12	Q1 2025 earnings	Positive	+4.3%	Q1 2025 results with early Plinabulin data and SEED preclinical progress.
Apr 29	2023 year‑end earnings	Positive	-9.5%	Year‑end 2023 business update showing Plinabulin advances but sizable net loss.

Pattern Detected

Across prior earnings and business updates, BYSI often saw negative next‑day reactions even when clinical narratives were constructive, with 3 of 4 recent earnings‑tagged releases followed by share price declines.

Recent Company History

Over the last year, BYSI’s earnings releases have consistently combined financial updates with Plinabulin clinical data and SEED developments. Q1–Q3 2025 results highlighted encouraging NSCLC and immunotherapy‑resistant outcomes alongside continuing net losses and reliance on SEED monetization. A 2023 year‑end update similarly paired pipeline progress with sizeable loss figures. Today’s 2025 year‑end release continues this pattern, adding DUBLIN‑3 survival confirmation, a planned DUBLIN‑4 Phase 3, and SEED’s first‑in‑human RBM39 degrader trial to the financial narrative.

Historical Comparison

-2.3% avg move · In the past four earnings‑tagged releases, BYSI’s average next‑day move was -2.34%, often skewing ne...

earnings

-2.3%

Average Historical Move earnings

In the past four earnings‑tagged releases, BYSI’s average next‑day move was -2.34%, often skewing negative despite generally constructive clinical and SEED updates. This year‑end 2025 report fits the pattern of pairing financial losses with advancing oncology programs.

Earnings updates progressed from 2023 year‑end through Q1–Q3 2025 to full‑year 2025, consistently building the Plinabulin story—from early PD‑1/L1‑failure data to large Phase 3 DUBLIN‑3 survival results and now a planned DUBLIN‑4 confirmatory trial, while SEED moved from preclinical work to first‑in‑human RBM39 degradation.

Market Pulse Summary

This announcement combines full‑year 2025 financials with maturing Plinabulin data and SEED’s first‑...

Analysis

This announcement combines full‑year 2025 financials with maturing Plinabulin data and SEED’s first‑in‑human RBM39 program. DUBLIN‑3 delivered an OS hazard ratio of 0.72 and a 2.5‑month median OS gain, while continuing operations reported a net loss of $8.7M and cash of $12.6M. Investors may track execution on the DUBLIN‑4 confirmatory trial, SEED clinical progress, expense trends, and future financing steps as key markers.

Key Terms

overall survival, hazard ratio, progression-free survival, disease control rate, +3 more

7 terms

overall survival medical

"demonstrated statistically significant overall survival benefit vs. standard of care docetaxel"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

hazard ratio medical

"the combination achieved: OS hazard ratio (HR) of 0.72 (p=0.0078)"

A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.

progression-free survival medical

"demonstrated: Median progression-free survival (PFS) of 7.0 months"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

disease control rate medical

"Disease control rate (DCR) of 85% and overall response rate (ORR) of 18.2%"

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

overall response rate medical

"Disease control rate (DCR) of 85% and overall response rate (ORR) of 18.2%"

Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.

orphan drug regulatory

"ST-01156, a novel oral RBM39 degrader: Received U.S. FDA Orphan Drug and Rare Pediatric Disease Designations"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

rare pediatric disease regulatory

"Received U.S. FDA Orphan Drug and Rare Pediatric Disease Designations"

A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.

AI-generated analysis. Not financial advice.

Plinabulin (BeyondSpring's Lead Program):

• Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine
• Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient population progressed on immune checkpoint inhibitors (NCT07361484)
• Overcoming Immunotherapy Resistance: Early clinical data at MD Anderson Cancer Center and Peking Union Hospital suggest Plinabulin may restore sensitivity to checkpoint inhibitors — a significant unmet need affecting most patients on PD-1/PD-L1 therapies – Results published in Cell Press journal Med 2025 and presented at SITC 2025
  

SEED Therapeutics (Reported as Discontinued Operations):

• First Patient Dosed for lead oncology program: ST-01156, a novel oral RBM39 degrader, initiated Phase 1a clinical trials in January 2026 following IND clearance in both the U.S. and China
• Financing Strengthened: Completed $30 million Series A-3 financing; appointed Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the year ended December 31, 2025, and highlighted late-stage clinical progress for Plinabulin and strategic developments related to its equity interest in SEED Therapeutics (“SEED”).

2025: Clinical and Operational Progress
“2025 was a year of important clinical and operational progress for BeyondSpring and SEED Therapeutics,” said Dr. Lan Huang, Co-Founder, Chairman and Chief Executive Officer of BeyondSpring. “We advanced our Phase 3 Plinabulin program, generated meaningful clinical data, and strengthened our strategic and financial position.”

“BeyondSpring made meaningful progress advancing Plinabulin in Phase 3 NSCLC, while SEED Therapeutics reached a critical milestone — initiating its first clinical trial following IND clearance in both the U.S. and China — and strengthened its leadership team and capital resources.”

Positioned for 2026 and Beyond
“With a solid scientific and clinical foundation and clear regulatory pathways, we believe BeyondSpring and SEED are well positioned for the next stage of development,” Dr. Huang concluded. “As we enter 2026, we remain focused on advancing the DUBLIN-4 confirmatory trial for Plinabulin in non-squamous EGFR wild-type NSCLC post immune checkpoint inhibitors, supporting SEED’s Phase 1a clinical program for ST-01156 in solid tumors, and creating long-term value for our shareholders.”

Recent Clinical and Business Updates
Plinabulin Demonstrates Overall Survival Benefit in Phase 3 NSCLC Study; Confirmatory Trial Planned
There is a significant unmet need in EGFR wild-type NSCLC following immune checkpoint inhibitor (ICI) therapy, where numerous Phase 3 studies have failed to improve overall survival over standard of care docetaxel.

BeyondSpring reported positive Phase 3 results from the DUBLIN-3 study evaluating plinabulin in combination with docetaxel in second- and third-line (2/3L) EGFR wild-type non-small cell lung cancer (NSCLC). The study demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to docetaxel alone (ITT, n=559), with results published in The Lancet Respiratory Medicine.

At IASLC North America and ESMO Asia in December 2025, BeyondSpring presented updated data from the mechanism-targeted non-squamous NSCLC population (n=332; 24-month after database lock), in which the combination achieved:

• OS hazard ratio (HR) of 0.72 (p=0.0078)
• Median OS improvement of 2.5 months vs. docetaxel
• Doubling of 2-year and 3-year survival rates
• Favorable safety profile, reducing grade 4 neutropenia from >30% to 5% (p<0.0001)

To date, over 700 patients have been treated with plinabulin across clinical studies, supporting the characterization of its safety and tolerability profile.

Based on these findings and discussions with the U.S. FDA, BeyondSpring plans to initiate the global Phase 3 DUBLIN-4 confirmatory study, focusing on a mechanism-enriched patient population of EGFR wild-type non-squamous NSCLC progressed on prior PD-1/L1 inhibitors with overall survival as the primary endpoint (NCT07361484).

Plinabulin Shows Potential to Overcome PD-1/PD-L1 Resistance
Emerging clinical data suggests plinabulin may help address acquired resistance to PD-1/PD-L1 therapies — a major challenge affecting approximately 60% of patients, with limited therapies for these progressed patients. With PD-1/PD-L1 therapies representing a multi-billion-dollar market, addressing resistance remains one of the most significant opportunities in oncology.

Presentations at ASCO 2025 and SITC 2025 on multiple early-stage and investigator-initiated studies of Plinabulin combinations:

• Plinabulin + pembrolizumab + docetaxel (303 study, NCT05599789): A Phase 2 study conducted at Peking Union Hospital in China in metastatic NSCLC patients progressing on PD-1/PD-L1 inhibitors (n=47) demonstrated:
  • Median progression-free survival (PFS) of 7.0 months
  • Disease control rate (DCR) of 85% and overall response rate (ORR) of 18.2%
  • Median OS not reached with 24-month overall survival rate of 66%
  • Whole blood analysis indicated higher proportions of activated CD4+/CD8+ T-cells post treatment
    
    
• Plinabulin + PD-1 inhibitor + radiation (NCT04902040): A Phase 1 study conducted at MD Anderson Cancer Center across eight tumor types resistant to checkpoint inhibitors showed:
  
  • DCR of 54% and ORR of 23%
  • Mechanistic evidence of dendritic cell maturation and immune activation
  • Identification of a potential predictive biomarker (GEF-H1 immune signature)
  • These findings, published in Med 2025 (Cell Press), support plinabulin’s proposed immune-priming mechanism and its potential role in combination strategies to restore tumor sensitivity to immunotherapy
    

BeyondSpring Business Update

• In January 2025, BeyondSpring entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED for gross proceeds of approximately $35.4 million to advance late-stage clinical development of Plinabulin. First closing of approximately $7.35 million was completed in February 2025.
  

SEED Therapeutics (Reported as Discontinued Operations) Advances First Clinical Program and Strengthens Organization
SEED Therapeutics continued to make progress in 2025 and early 2026, advancing its targeted protein degradation platform and pipeline.

Key highlights include:

• ST-01156, a novel oral RBM39 degrader:
  • Received U.S. FDA Orphan Drug and Rare Pediatric Disease Designations
  • Achieved IND clearance in both the U.S. and China
  • Dosed first patient in a Phase 1a study in January 2026
• ST-01156 Phase 1a enrolling at leading U.S. cancer centers: Dana-Farber, Massachusetts General Hospital, Memorial Sloan Kettering, MD Anderson Cancer Center, Hoag, and City of Hope
• Presentation at AACR 2025 on ST-01156 mechanism and preclinical studies including complete tumor regression in Ewing sarcoma and other cancer models; new degrader approaches in KRAS G12D degradation

SEED Business Update

• Completed a $30 million Series A-3 financing
• Appointed Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
• Named a finalist for the 2025 Prix Galien USA “Best Start-Up” Award
  

Full-Year 2025 Financial Results¹
Continuing operations:

• R&D expenses: $4.4 million (vs. $2.6 million in 2024), driven by increased drug manufacturing, NSCLC data management, Plinabulin combination research, regulatory consulting, and personnel costs
• G&A expenses: $4.6 million (vs. $6.1 million in 2024), driven by lower personnel costs, reduced consulting expenses, and lower corporate overhead
• Net loss: $8.7 million (vs. $8.9 million in 2024)
• Cash, cash equivalents, and short-term investments: $12.6 million as of December 31, 2025

Discontinued operations:

• Net loss: $5.5 million (vs. $7.8 million in 2024)
• Current assets: $8.0 million as of December 31, 2025

Note 1. As a result of BeyondSpring entering into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED, SEED’s operations met the criteria as discontinued operations under ASC 205-20 for financial reporting purposes.

About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to restoring tumor sensitivity to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

About SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by undruggable proteins. Its proprietary RITE3™ platform enables targeted protein degradation with small-molecule precision. SEED’s lead candidate, ST-01156, is a brain-penetrant RBM39 degrader entering clinical development for Ewing sarcoma and other RBM39-dependent cancers. Eli Lilly and Eisai are investors and research collaborators with SEED Therapeutics. The company’s pipeline includes six programs across oncology, neurodegeneration, immunology, and virology. Learn more at seedtherapeutics.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company’s expectations regarding the potential safety, the ultimate efficacy or clinical utility of the Company’s product candidates, increased competition in the market, the ability to complete the sale of BeyondSpring’s equity interest in SEED Therapeutics on terms acceptable to BeyondSpring, if at all, the Company’s ability to meet Nasdaq’s continued listing requirements, and other risks described in BeyondSpring’s most recent Form 10-K on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

Financial Tables to Follow

BEYONDSPRING INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
	As of December 31,
	2024		2025
	$		$
Assets
Current assets:
Cash and cash equivalents	2,922		7,786
Short-term investments	-		4,775
Advances to suppliers	240		227
Prepaid expenses and other current assets	68		71
Current assets of discontinued operations	25,347		8,023
Total current assets	28,577		20,882
Noncurrent assets:
Property and equipment, net	239		166
Operating right-of-use assets	513		305
Other noncurrent assets	213		224
Noncurrent assets of discontinued operations	4,773		4,356
Total noncurrent assets	5,738		5,051
Total assets	34,315		25,933
Liabilities and equity
Current liabilities:
Accounts payable	295		363
Accrued expenses	840		938
Current portion of operating lease liabilities	282		320
Other current liabilities	780		822
Current liabilities of discontinued operations	8,813		11,133
Total current liabilities	11,010		13,576
Noncurrent liabilities:
Operating lease liabilities	307		-
Deferred revenue	27,400		28,600
Other noncurrent liabilities	3,686		3,981
Noncurrent liabilities of discontinued operations	6,197		3,766
Total noncurrent liabilities	37,590		36,347
Total liabilities	48,600		49,923
Shareholders’ deficit
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 40,316,320 and 41,122,320 shares issued and outstanding as of December 31, 2024 and 2025, respectively)	4		4
Additional paid-in capital	373,185		375,664
Accumulated deficit	(407,425	)	(408,431	)
Accumulated other comprehensive income	1,336		602
Total BeyondSpring Inc.’s shareholders’ deficit	(32,900	)	(32,161	)
Noncontrolling interests	18,615		8,171
Total shareholders’ deficit	(14,285	)	(23,990	)
Total liabilities and shareholders’ deficit	34,315		25,933

BEYONDSPRING INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)
		Year ended December 31,
		2024			2025
		$			$
Revenue		-			-
Operating expenses
Research and development		(2,644		)	(4,388		)
General and administrative		(6,110		)	(4,557		)
Loss from operations		(8,754		)	(8,945		)
Foreign exchange gain (loss), net		(96		)	165
Interest income		59			78
Other income, net		22			77
Loss before income tax		(8,769		)	(8,625		)
Income tax expenses		(96		)	(90		)
Net loss from continuing operations		(8,865		)	(8,715		)
Discontinued operations
Loss from discontinued operations		(7,828		)	(12,488		)
Gain on disposal of discontinued operations		-			6,986
Income tax expenses		-			-
Net loss from discontinued operations		(7,828		)	(5,502		)
Net loss		(16,693		)	(14,217		)
Less: Net loss attributable to noncontrolling interests from continuing operations		(388		)	(242		)
Less: Net loss attributable to noncontrolling interests from discontinued operations		(5,182		)	(12,969		)
Net loss attributable to BeyondSpring Inc.		(11,123		)	(1,006		)
Net earnings (loss) per share, basic and diluted
Continuing operations		(0.21		)	(0.21		)
Discontinued operations		(0.07		)	0.19
Basic and diluted loss per share		(0.28		)	(0.02		)
Weighted-average shares outstanding
Basic and diluted		39,733,191			40,406,347
Other comprehensive loss, net of tax of nil:
Foreign currency translation adjustment gain (loss) from continuing operations		710			(1,147		)
Foreign currency translation adjustment gain (loss) from discontinued operations		17			(107		)
Comprehensive loss		(15,966		)	(15,471		)
Less: Comprehensive loss attributable to noncontrolling interests from continuing operations		(131		)	(655		)
Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations		(5,154		)	(13,076		)
Comprehensive loss attributable to BeyondSpring Inc.		(10,681		)	(1,740		)

FAQ

What did BeyondSpring (BYSI) report for plinabulin in the DUBLIN-3 Phase 3 NSCLC study?

The DUBLIN-3 trial showed a statistically significant overall survival benefit (OS HR 0.72, p=0.0078). According to the company, median overall survival improved by 2.5 months and 2- and 3-year survival rates doubled versus docetaxel.

What is BeyondSpring's plan for a confirmatory trial for plinabulin (BYSI) after DUBLIN-3?

BeyondSpring plans a global confirmatory Phase 3 study named DUBLIN-4 (NCT07361484) focused on EGFR wild-type non-squamous NSCLC post PD-1/L1 inhibitors. According to the company, overall survival will be the primary endpoint in a biomarker-selected population.

How did plinabulin affect safety outcomes in the Phase 3 DUBLIN-3 results for BYSI?

Plinabulin plus docetaxel markedly reduced severe neutropenia to 5% from >30%. According to the company, the combination showed a favorable safety profile while delivering the observed survival benefit.

What recent clinical progress did SEED Therapeutics report related to BeyondSpring's discontinued operations?

SEED advanced ST-01156 into a Phase 1a study and dosed its first patient after IND clearances in the U.S. and China. According to the company, SEED also completed a $30M Series A-3 financing and expanded its leadership team.

What are BeyondSpring's key 2025 financials and liquidity as of Dec 31, 2025 (BYSI)?

Continuing operations showed R&D expense of $4.4M, G&A of $4.6M, and a net loss of $8.7M. According to the company, cash, cash equivalents, and short-term investments totaled $12.6M at year-end.